Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El-Mansoura, Egypt; Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt.
Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El-Mansoura, Egypt; Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt.
J Hepatol. 2021 Feb;74(2):303-311. doi: 10.1016/j.jhep.2020.09.008. Epub 2020 Sep 12.
BACKGROUND & AIMS: Egypt has a major HCV burden and a well established treatment programme, with an ambitious goal of HCV elimination. Our aim was to assess the impact of a comprehensive HCV prevention, test and treat programme on the incidence of new HCV infections in 9 villages in rural Egypt. METHODS: An HCV "educate, test and treat" project was implemented in 73 villages across 7 governorates in Egypt between 06/2015 and 06/2018. In 2018, in 9 of the villages we re-tested individuals who originally tested HCV antibody (HCV-Ab) and HBsAg negative using rapid diagnostic tests (RDTs); confirmatory HCV RNA testing was performed for positive cases. The incidence rate per 1,000 person-years (py) was calculated, and risk factors for incident HCV infections assessed through an interviewer-administered questionnaire in 1:3 age- and gender-matched cases and controls. RESULTS: Out of 20,490 individuals who originally tested HCV-Ab negative in the 9 villages during the 2015-2016 implementation of the "educate, test and treat" programme, 19,816 (96.7%) were re-tested in 2018. Over a median of 2.4 years (IQR 2.1-2.7), there were 19 new HCV infections all of which were HCV RNA positive (incidence rate 0.37/1,000 py) (95% CI 0.24-0.59). Compared to a previous estimate of incidence in the Nile Delta region (2.4/1,000 py) from 2006, there was a substantial reduction in overall incidence of new HCV infections. Exposures through surgery (odds ratio 51; 95% CI 3.5-740.1) and dental procedures (odds ratio 23.8; 95% CI 2.9-194.9) were significant independent predictors of incident infections. CONCLUSIONS: This is the first study to show a substantial reduction in incidence of new HCV infections in a sample of the general population in Egypt following attainment of high testing and treatment coverage. New infections were significantly associated with healthcare-associated exposures. LAY SUMMARY: Egypt has a major national HCV testing and treatment programme with the goal of eliminating HCV infection. We assessed the impact of a comprehensive HCV prevention, test and treat programme in 73 villages that achieved high coverage of testing and treatment on the subsequent incidence of new HCV infections in nine of the villages. We re-tested people who were previously HCV antibody negative and found that the rate of new HCV infections was greatly reduced compared to previous estimates. We also found that exposure through surgery and dental procedures were associated with these new infections. This highlights the importance of continued strengthening of infection control and prevention measures, alongside treatment scale-up.
背景与目的:埃及 HCV 负担沉重,且拥有成熟的治疗项目,设定了消除 HCV 的宏伟目标。本研究旨在评估在埃及农村的 9 个村庄实施全面 HCV 预防、检测和治疗项目对新 HCV 感染发病率的影响。
方法:2015 年 6 月至 2018 年 6 月期间,在埃及 7 个省的 73 个村庄实施了 HCV“教育、检测和治疗”项目。2018 年,我们对最初使用快速诊断检测(RDT)检测 HCV 抗体(HCV-Ab)和 HBsAg 均为阴性的个体进行了重新检测;对阳性病例进行了 HCV RNA 确认检测。通过对年龄和性别匹配的 1:3 例病例和对照进行访谈式问卷调查,评估了新 HCV 感染的发生率,并评估了新 HCV 感染的危险因素。
结果:在 2015-2016 年实施“教育、检测和治疗”项目期间,最初在 9 个村庄中检测 HCV-Ab 为阴性的 20490 人中,有 19816 人(96.7%)在 2018 年接受了重新检测。中位随访时间为 2.4 年(IQR 2.1-2.7),共发现 19 例新 HCV 感染,均为 HCV RNA 阳性(发病率 0.37/1000 人年)(95%CI 0.24-0.59)。与 2006 年尼罗河三角洲地区的 HCV 发病率(2.4/1000 人年)相比,新 HCV 感染的总发病率有了显著降低。手术(比值比 51;95%CI 3.5-740.1)和牙科手术(比值比 23.8;95%CI 2.9-194.9)的暴露是新感染的独立危险因素。
结论:本研究首次显示,在埃及一般人群中,在达到高检测和治疗覆盖率后,新 HCV 感染的发病率显著降低。新感染与医疗相关的暴露显著相关。
简而言之:埃及有一个重要的全国性 HCV 检测和治疗项目,目标是消除 HCV 感染。我们评估了在 73 个实现高检测和治疗覆盖率的村庄实施全面 HCV 预防、检测和治疗方案对其中 9 个村庄随后发生的新 HCV 感染发病率的影响。我们对之前 HCV 抗体阴性的人进行了重新检测,发现新 HCV 感染率与之前的估计相比大大降低。我们还发现,手术和牙科手术暴露与这些新感染有关。这突显了继续加强感染控制和预防措施以及扩大治疗规模的重要性。
Lancet Gastroenterol Hepatol. 2018-7-18
World J Gastroenterol. 2018-7-21
PLoS Comput Biol. 2025-2-24
Pathogens. 2024-8-12
Lancet Reg Health Eur. 2023-12-13
Emerg Microbes Infect. 2022-12
World J Hepatol. 2022-1-27
Lancet Gastroenterol Hepatol. 2022-4